Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Danai Sfantou"'
Autor:
Dimitrios Alexopoulos, Danai Sfantou, Ioannis Lianos, Christos Pappas, Ioanna Revela, Helen Triantafyllidi, Ignatios Ikonomidis
Publikováno v:
Platelets, Vol 31, Iss 6, Pp 812-814 (2020)
Given that patients with prior myocardial infarction and features of high ischemic and low bleeding risk may benefit by extending dual antiplatelet therapy beyond 1 year, we aimed of assessing platelet reactivity provided by ticagrelor 60 mg bid vers
Externí odkaz:
https://doaj.org/article/c38ebb3094db48c0b316448bad126867
Publikováno v:
Platelets, Vol 29, Iss 3, Pp 228-237 (2018)
In seeking to improve care in coronary artery disease patients, further platelet inhibition has been occasionally applied beyond that provided by aspirin and a P2Y12 receptor antagonist. This review aims to offer insights about the rationale, the eff
Externí odkaz:
https://doaj.org/article/139bdc14e95a4105b9ed399f0afc8ef7
Publikováno v:
Platelets. 29:228-237
In seeking to improve care in coronary artery disease patients, further platelet inhibition has been occasionally applied beyond that provided by aspirin and a P2Y12 receptor antagonist. This review aims to offer insights about the rationale, the eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::873eece0d6ed0112eac44ab0f6dcf624
https://doi.org/10.1080/09537104.2017.1353685
https://doi.org/10.1080/09537104.2017.1353685
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 23:13-22
Cangrelor is an intravenously administered P2Y12 receptor antagonist with very fast, potent, and quickly reversible action. In the CHAMPION PHOENIX trial, cangrelor provided an improved anti-ischemic protection compared with clopidogrel, without incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9762660ba99659dd4568d18841cc55b5
https://doi.org/10.1177/1074248417715004
https://doi.org/10.1177/1074248417715004
Autor:
Christos Pappas, Ioannis Lianos, Ioanna Revela, Dimitrios Alexopoulos, Ignatios Ikonomidis, Helen Triantafyllidi, Danai Sfantou
Publikováno v:
Platelets. 31(6)
Given that patients with prior myocardial infarction and features of high ischemic and low bleeding risk may benefit by extending dual antiplatelet therapy beyond 1 year, we aimed of assessing platelet reactivity provided by ticagrelor 60 mg bid vers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dcd8bf65f401d592e767826f3a9d2c7
https://pubmed.ncbi.nlm.nih.gov/31608799
https://pubmed.ncbi.nlm.nih.gov/31608799
Autor:
Vassiliki-Maria Dragona, Ioannis Lianos, Danai Sfantou, Panagiotis Vlachakis, Dimitrios Alexopoulos, Charalambos Varlamos
Publikováno v:
Journal of cardiovascular pharmacology and therapeutics. 24(4)
In patients with an acute coronary syndrome undergoing percutaneous coronary intervention, novel P2Y12 receptor inhibitors, prasugrel and ticagrelor, are proposed as "first-line" antiplatelet agents in the absence of contraindications and up to a yea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1f7abe41c9e68a6602ba672e99f25cd
https://pubmed.ncbi.nlm.nih.gov/30722685
https://pubmed.ncbi.nlm.nih.gov/30722685
Autor:
Christos Pappas, Petros Kikas, Dimitris Tziakas, Efstathios K. Iliodromitis, Haralambos Karvounis, Ioanna Xanthopoulou, Danai Sfantou, Dimitrios Alexopoulos, Antonios Ziakas, Matthaios Didagelos
Publikováno v:
Journal of the American College of Cardiology. 72:1750-1751
The intravenous P2Y12 receptor antagonist cangrelor provides rapid onset and offset of platelet inhibition [(1)][1]. Compared with clopidogrel, cangrelor has significantly reduced the rate of ischemic events, including stent thrombosis, during percut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d52ffbb2404ef9352a3c6e77697c9a
https://doi.org/10.1016/j.jacc.2018.07.041
https://doi.org/10.1016/j.jacc.2018.07.041